Thymus Reconstitution in Young and Aged Mice Is Facilitated by

T cell development hematopoietic stem cell (HSC) transplantation homing progenitor T cells thymus

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 23 04 2022
accepted: 13 06 2022
entrez: 25 7 2022
pubmed: 26 7 2022
medline: 27 7 2022
Statut: epublish

Résumé

The prolonged lag in T cell recovery seen in older patients undergoing hematopoietic stem cell transplant (HSCT), after chemo-/radiotherapy, can lead to immune dysfunction. As a result, recovering patients may experience a relapse in malignancies and opportunistic infections, leading to high mortality rates. The delay in T cell recovery is partly due to thymic involution, a natural collapse in the size and function of the thymus, as individuals age, and partly due to the damage sustained by the thymic stromal cells through exposure to chemo-/radiotherapy. There is a clear need for new strategies to accelerate intrathymic T cell reconstitution when treating aged patients to counter the effects of involution and cancer therapy regimens. Adoptive transfer of human progenitor T (proT) cells has been shown to accelerate T cell regeneration in radiation-treated young mice and to restore thymic architecture in immunodeficient mice. Here, we demonstrate that the adoptive transfer of

Identifiants

pubmed: 35874726
doi: 10.3389/fimmu.2022.926773
pmc: PMC9304753
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

926773

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL147584
Pays : United States

Informations de copyright

Copyright © 2022 Mohtashami, Li, Lee and Zúñiga-Pflücker.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Blood. 2011 Nov 24;118(22):5723-31
pubmed: 21908422
Nat Methods. 2017 May;14(5):531-538
pubmed: 28394335
Nat Commun. 2021 Aug 18;12(1):5023
pubmed: 34408144
Annu Rev Immunol. 2007;25:649-79
pubmed: 17291187
Breast Cancer Res. 2016 Jan 26;18(1):10
pubmed: 26810608
Nat Med. 2006 Sep;12(9):1039-47
pubmed: 16936725
Immun Ageing. 2008 Feb 11;5:1
pubmed: 18267021
Curr Opin Hematol. 2016 Mar;23(2):95-101
pubmed: 26825695
Nucleic Acids Res. 2005 Mar 22;33(5):e51
pubmed: 15784609
Cell Rep. 2015 Aug 18;12(7):1071-9
pubmed: 26257169
J Exp Med. 2007 Jun 11;204(6):1267-72
pubmed: 17502664
Nat Biotechnol. 2008 Apr;26(4):453-61
pubmed: 18376399
Hematology Am Soc Hematol Educ Program. 2012;2012:265-70
pubmed: 23233590
JCI Insight. 2017 May 18;2(10):
pubmed: 28515359
J Immunol. 2005 Sep 1;175(5):2982-93
pubmed: 16116185
Trends Immunol. 2009 Jul;30(7):366-73
pubmed: 19540807
Front Immunol. 2016 Nov 17;7:507
pubmed: 27909435
Clin Transl Sci. 2009 Aug;2(4):279-85
pubmed: 19750208
Stem Cells. 2012 Aug;30(8):1771-80
pubmed: 22689616
Aging Cell. 2008 Mar;7(2):158-67
pubmed: 18241323
Cell Rep. 2019 Jun 25;27(13):3887-3901.e4
pubmed: 31242421
Front Immunol. 2020 Aug 18;11:1850
pubmed: 32973763
Nat Rev Immunol. 2021 May;21(5):277-291
pubmed: 33097917
Int Immunol. 2007 Oct;19(10):1201-11
pubmed: 17804689
Biol Blood Marrow Transplant. 1997 Jun;3(2):65-75
pubmed: 9267666
Curr Opin Immunol. 2010 Aug;22(4):521-8
pubmed: 20650623
J Immunol. 2012 Dec 15;189(12):5519-26
pubmed: 23152561
Eur J Immunol. 2015 Mar;45(3):932-42
pubmed: 25408420
Cell Rep. 2022 Feb 15;38(7):110363
pubmed: 35172147
Mech Ageing Dev. 1995 Aug 8;82(2-3):155-70
pubmed: 8538244
Blood. 2013 Dec 19;122(26):4210-9
pubmed: 24215033
Development. 2005 Jan;132(1):203-13
pubmed: 15576407
J Immunol. 2009 Jul 15;183(2):823-31
pubmed: 19564346
Aging Cell. 2015 Apr;14(2):153-61
pubmed: 25645467
Immun Ageing. 2015 Oct 29;12:18
pubmed: 26516334
Annu Rev Immunol. 1996;14:29-47
pubmed: 8717506
Eur J Haematol. 2022 Apr;108(4):288-297
pubmed: 34905239
Immunol Rev. 2006 Feb;209:58-75
pubmed: 16448534
Exp Gerontol. 2018 May;105:113-117
pubmed: 29278750
Immunity. 2008 Sep 19;29(3):438-50
pubmed: 18799150
Lab Invest. 2019 Jan;99(1):93-106
pubmed: 30353130

Auteurs

Mahmood Mohtashami (M)

Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.

Yue Ru Li (YR)

Department of Immunology, University of Toronto, Toronto, ON, Canada.

Christina R Lee (CR)

Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.

Juan Carlos Zúñiga-Pflücker (JC)

Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
Department of Immunology, University of Toronto, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH